Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LAN LUO

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1295938975
CMS profile
59296
Location
OCALA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,489.01

74 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,475.12 72
Consulting Fee $1,000.00 1
Education $13.89 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LAN LUO

NPI 1295938975 · CMS profile ID 59296

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

OCALA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295938975?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LAN LUO, NPI 1295938975, CMS profile ID 59296. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295938975?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). LAN LUO, NPI 1295938975, CMS profile ID 59296. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295938975?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
LAN LUO, NPI 1295938975, CMS profile ID 59296, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1295938975?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

74 matching records · $2,489.01 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 74 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–74 of 74.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
CashFlow Solutions, LLC $17.1905/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964326463 CMS
Janssen Pharmaceuticals, Inc $3.3705/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885978351 CMS
Merck Sharp & Dohme LLC $12.9204/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944435163 CMS
E.R. Squibb & Sons, L.L.C. $18.6904/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932595077 CMS
Amarin Pharma Inc. $15.1504/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 913943907 CMS
Esperion Therapeutics, Inc. $19.6404/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947268607 CMS
Janssen Pharmaceuticals, Inc $10.6304/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885978329 CMS
Merck Sharp & Dohme LLC $15.4403/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944424325 CMS
Novartis Pharmaceuticals Corporation $11.7603/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893915527 CMS
E.R. Squibb & Sons, L.L.C. $14.0003/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932595075 CMS
Merck Sharp & Dohme LLC $8.9903/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944432297 CMS
AstraZeneca Pharmaceuticals LP $12.1703/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920251953 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $26.6503/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 876337643 CMS
PFIZER INC. $13.5803/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949088345 CMS
Amgen Inc. $16.4803/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939280617 CMS
Amarin Pharma Inc. $14.7002/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 913917261 CMS
Merck Sharp & Dohme LLC $9.2802/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944431639 CMS
Novartis Pharmaceuticals Corporation $14.0802/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893915523 CMS
Amgen Inc. $12.6202/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939280609 CMS
Janssen Pharmaceuticals, Inc $14.8702/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885978317 CMS
Novartis Pharmaceuticals Corporation $19.3801/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893915519 CMS
Merck Sharp & Dohme LLC $24.2801/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944432241 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.3001/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887695299 CMS
Amarin Pharma Inc. $17.8701/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 913915749 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,266.02 81
PY2020 $2,392.86 52
PY2021 $1,425.65 86
PY2022 $2,489.01 74
PY2023 $1,389.27 70
PY2024 $1,213.55 52
PY2025 $1,081.15 47

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $763,173.85 134
PY2024 Principal investigator $505,042.12 14
PY2023 Principal investigator $445,589.26 11
PY2022 Principal investigator $317,610.34 10
PY2021 Recipient $1,096.66 1
PY2021 Principal investigator $288,935.86 16
PY2020 Recipient $52,826.68 8
PY2020 Principal investigator $168,475.28 31
PY2019 Recipient $12,009.00 3
PY2019 Principal investigator $155,369.67 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

134 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $32.39 12/31/2025 Non-covered Recipient Entity
MORGAN MEDICAL MANAGEMENT CONSULT OCALA CARDIOVASCULAR RESEARCH
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190312047
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,000.00 12/19/2025 Non-covered Recipient Entity
OCALA CARDIOVASCULAR RESEARCH
A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a) No dispute reported 06/30/2026 1190314085
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 12/17/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220997308
Principal investigator 1 Boehringer Ingelheim International GmbH $304.00 12/15/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732942
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 12/15/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732944
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 12/15/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732946
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 12/15/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732948
Principal investigator 1 Boehringer Ingelheim International GmbH $2,611.00 12/15/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732950
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 12/03/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220997310
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732938
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732940
Principal investigator 1 Amgen Inc. $70,327.44 11/25/2025 Non-covered Recipient Entity
MORGAN MEDICAL MANAGEMENT & CONSULTANTS, INC. D/B/A OCALA CARDIOVASCULAR RESEARCH
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246644887
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,252.00 11/20/2025 Non-covered Recipient Entity
MORGAN MEDICAL MANAGEMENT CONSULT OCALA CARDIOVASCULAR RESEARCH
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190312049
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 11/19/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732932
Principal investigator 1 Boehringer Ingelheim International GmbH $2,611.00 11/19/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732934
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 11/19/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732936
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 11/12/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220997304
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 11/11/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220997306
Principal investigator 1 Ionis Pharmaceuticals, Inc. $3,030.20 11/11/2025 Non-covered Recipient Entity
MORGAN MEDICAL MANAGEMENT & CONSULTANTS INC DBA OCALA CARDIOVASCULAR RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246790308
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,639.24 11/05/2025 Non-covered Recipient Entity
OCALA CARDIOVASCULAR RESEARCH
A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a) No dispute reported 06/30/2026 1190314083
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732928
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732930
Principal investigator 1 Boehringer Ingelheim International GmbH $2,611.00 10/20/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732926
Principal investigator 1 Ionis Pharmaceuticals, Inc. $550.00 10/08/2025 Non-covered Recipient Entity
MORGAN MEDICAL MANAGEMENT & CONSULTANTS INC DBA OCALA CARDIOVASCULAR RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246788392
Principal investigator 1 Ionis Pharmaceuticals, Inc. $976.12 10/08/2025 Non-covered Recipient Entity
MORGAN MEDICAL MANAGEMENT & CONSULTANTS INC DBA OCALA CARDIOVASCULAR RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246788396
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,600.00 10/08/2025 Non-covered Recipient Entity
MORGAN MEDICAL MANAGEMENT & CONSULTANTS INC DBA OCALA CARDIOVASCULAR RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246788400
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,650.00 10/08/2025 Non-covered Recipient Entity
MORGAN MEDICAL MANAGEMENT & CONSULTANTS INC DBA OCALA CARDIOVASCULAR RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246788404
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,700.00 10/08/2025 Non-covered Recipient Entity
MORGAN MEDICAL MANAGEMENT & CONSULTANTS INC DBA OCALA CARDIOVASCULAR RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246788407
Principal investigator 1 Novartis Pharmaceuticals Corporation $26,699.57 10/07/2025 Non-covered Recipient Entity
OCALA CARDIOVASCULAR RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C No dispute reported 06/30/2026 1190312525
Principal investigator 1 Boehringer Ingelheim International GmbH $2,611.00 10/02/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732912
Principal investigator 1 Boehringer Ingelheim International GmbH $3,023.00 10/02/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732914
Principal investigator 1 Boehringer Ingelheim International GmbH $2,017.00 10/02/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732916
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 10/02/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732918
Principal investigator 1 Boehringer Ingelheim International GmbH $2,611.00 10/02/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732920
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 10/02/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732922
Principal investigator 1 Boehringer Ingelheim International GmbH $2,393.00 10/02/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732924
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732908
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732910
Principal investigator 1 Novartis Pharmaceuticals Corporation $86.68 09/30/2025 Non-covered Recipient Entity
MORGAN MEDICAL MANAGEMENT CONSULT OCALA CARDIOVASCULAR RESEARCH
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190312053
Principal investigator 1 Boehringer Ingelheim International GmbH $439.56 09/24/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732808
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 09/24/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732810
Principal investigator 1 Boehringer Ingelheim International GmbH $8.70 09/24/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732812
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732804
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732806
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 08/20/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732836
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 08/20/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732838
Principal investigator 1 Amgen Inc. $153,775.00 08/01/2025 Non-covered Recipient Entity
MORGAN MEDICAL MANAGEMENT & CONSULTANTS, INC. D/B/A OCALA CARDIOVASCULAR RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246644896
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732832
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732834
Principal investigator 1 Amgen Inc. $9,399.35 07/28/2025 Non-covered Recipient Entity
OCALA CARDIOVASCULAR RESEARCH
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246645795
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 07/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732830
Principal investigator 1 Boehringer Ingelheim International GmbH $2,393.00 07/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732874
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 07/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732876
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 07/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732878
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732870
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732872
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 06/24/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732850
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 06/20/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732900
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 06/20/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732902
Principal investigator 1 Boehringer Ingelheim International GmbH $2,393.00 06/20/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732904
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 06/20/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732906
Principal investigator 1 Eli Lilly and Company $4,700.00 06/09/2025 Non-covered Recipient Entity
MORGAN MEDICAL MANAGEMENT AND CONSULTANTS INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND OBESITY (SUMMIT No dispute reported 06/30/2026 1187887134
Principal investigator 1 Boehringer Ingelheim International GmbH $304.00 06/04/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732888
Principal investigator 1 Boehringer Ingelheim International GmbH $304.00 06/04/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732890
Principal investigator 1 Boehringer Ingelheim International GmbH $304.00 06/04/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732892
Principal investigator 1 Boehringer Ingelheim International GmbH $304.00 06/04/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732894
Principal investigator 1 Boehringer Ingelheim International GmbH $2,393.00 06/04/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732896
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 06/04/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732898
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732884
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732886
Principal investigator 1 Amgen Inc. $47,966.83 05/31/2025 Non-covered Recipient Entity
OCALA CARDIOVASCULAR RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246645802
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 05/13/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220997302
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732742
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732744
Principal investigator 1 Boehringer Ingelheim International GmbH $1,390.00 04/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732750
Principal investigator 1 Boehringer Ingelheim International GmbH $2,511.00 04/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732752
Principal investigator 1 Boehringer Ingelheim International GmbH $2,628.00 04/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732754
Principal investigator 1 Boehringer Ingelheim International GmbH $2,393.00 04/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732756
Principal investigator 1 Boehringer Ingelheim International GmbH $304.00 04/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732758
Principal investigator 1 Boehringer Ingelheim International GmbH $304.00 04/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732760
Principal investigator 1 Boehringer Ingelheim International GmbH $2,393.00 04/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732762
Principal investigator 1 Boehringer Ingelheim International GmbH $2,393.00 04/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732764
Principal investigator 1 Boehringer Ingelheim International GmbH $3,023.00 04/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732766
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 04/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732768
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 04/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732770
Principal investigator 1 Amgen Inc. $110,032.26 04/24/2025 Non-covered Recipient Entity
MORGAN MEDICAL MANAGEMENT & CONSULTANTS, INC. D/B/A OCALA CARDIOVASCULAR RESEARCH
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246644892
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,472.81 04/24/2025 Non-covered Recipient Entity
MORGAN MEDICAL MANAGEMENT CONSULT OCALA CARDIOVASCULAR RESEARCH
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190312051
Principal investigator 1 Boehringer Ingelheim International GmbH $1.55 04/23/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732846
Principal investigator 1 Boehringer Ingelheim International GmbH $8.40 04/23/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732848
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732746
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732748
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 03/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732844
Principal investigator 1 Boehringer Ingelheim International GmbH $1,390.00 03/19/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732772
Principal investigator 1 Boehringer Ingelheim International GmbH $3,226.00 03/19/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732774
Principal investigator 1 Boehringer Ingelheim International GmbH $3,226.00 03/19/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732776
Principal investigator 1 Boehringer Ingelheim International GmbH $1,390.00 03/19/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732778
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 03/19/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732780
Principal investigator 1 Boehringer Ingelheim International GmbH $2,511.00 03/19/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732782
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732798
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732800
Principal investigator 1 Boehringer Ingelheim International GmbH $3,226.00 02/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732786
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 02/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732788
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 02/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732790
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 02/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732792
Principal investigator 1 Boehringer Ingelheim International GmbH $2,511.00 02/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732794
Principal investigator 1 Boehringer Ingelheim International GmbH $1,925.00 02/25/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732796
Principal investigator 1 Eli Lilly and Company $1,098.00 02/25/2025 Non-covered Recipient Entity
MORGAN MEDICAL MANAGEMENT AND CONSULTANTS INC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187886590
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732784
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732828
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 01/31/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732802
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $18,361.64 01/31/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220997300
Principal investigator 1 Boehringer Ingelheim International GmbH $17.40 01/27/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732840
Principal investigator 1 Boehringer Ingelheim International GmbH $28.20 01/27/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732842
Principal investigator 1 Boehringer Ingelheim International GmbH $799.20 01/27/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732880
Principal investigator 1 Boehringer Ingelheim International GmbH $1,095.00 01/27/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732882
Principal investigator 1 Boehringer Ingelheim International GmbH $3,226.00 01/24/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732818
Principal investigator 1 Boehringer Ingelheim International GmbH $3,023.00 01/24/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732820
Principal investigator 1 Boehringer Ingelheim International GmbH $2,511.00 01/24/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732822
Principal investigator 1 Boehringer Ingelheim International GmbH $1,925.00 01/24/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732824
Principal investigator 1 Boehringer Ingelheim International GmbH $2,628.00 01/24/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732826
Principal investigator 1 AstraZeneca Pharmaceuticals LP $187.65 01/22/2025 Non-covered Recipient Entity
MORGAN MEDICAL MANAGEMENT & CONSULTANST
This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio No dispute reported 06/30/2026 1185554777
Principal investigator 1 Boehringer Ingelheim International GmbH $1,925.00 01/22/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732814
Principal investigator 1 Boehringer Ingelheim International GmbH $2,628.00 01/22/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732816
Principal investigator 1 Boehringer Ingelheim International GmbH $3,226.00 01/22/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732856
Principal investigator 1 Boehringer Ingelheim International GmbH $119.00 01/22/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732858
Principal investigator 1 Boehringer Ingelheim International GmbH $3,023.00 01/22/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732860
Principal investigator 1 Boehringer Ingelheim International GmbH $41.00 01/22/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732862
Principal investigator 1 Boehringer Ingelheim International GmbH $2,511.00 01/22/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732864
Principal investigator 1 Boehringer Ingelheim International GmbH $3,023.00 01/22/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732866
Principal investigator 1 Boehringer Ingelheim International GmbH $3,023.00 01/22/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732868
Principal investigator 1 Eli Lilly and Company $82,456.20 01/21/2025 Non-covered Recipient Entity
MORGAN MEDICAL MANAGEMENT AND CONSULTANTS INC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187884288
Principal investigator 1 Amgen Inc. $69,482.36 01/13/2025 Non-covered Recipient Entity
OCALA CARDIOVASCULAR RESEARCH
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246645798
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732852
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Central Florida Heart Center-Applewood Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220732854